News

November 26, 2019

Alpha DaRT™ achieves a 78.6% complete response rate in management of challenging squamous cell carcinoma tumors.


Tel Aviv, Israel, November 26, 2019 – Alpha Tau Medical is pleased to announce the publication of the results of its first clinical trial of Alpha DaRT™, a...

September 4, 2019

Alpha Tau Medical, developer of the breakthrough alpha radiation cancer therapy Alpha DaRT, announced today the appointment of Dr. Robert B. Den, MD, as Chief Medical Officer (CMO). In his new role, and as a prominent expert and accomplished clinician, Dr. Den will lea...

November 7, 2018

Trials will investigate the efficacy of its breakthrough cancer treatment, Alpha DaRT, in Squamous Cell Carcinoma (SCC) of the Skin, and Cutaneous and Mucosal malignant Neoplasia (CMN)

TEL AVIV, Israel--(BUSINESS WIRE)--Alpha Tau Medical, developer of a breakthrough alp...

August 23, 2018

The Massachusetts Radiation Control Program (RCP), in conjunction with the U.S. Nuclear Regulatory Commission (NRC), has approved Alpha Tau Medical’s Alpha DaRT cancer treatment as a Sealed Source and Device (SSD). 

https://www.dotmed.com/news/story/44162 

Granting of th...

August 22, 2018

[..] Another company from Tel Aviv, Alpha Tau Medical, has partnered with Japanese biotechnology startup HekaBio to release radiation therapy equipment in Japan in 2021, at the earliest.

The product is designed to treat patients with breast, skin and other solid cancers...

Please reload

Categories
Please reload

Sign up
Featured Posts

Breakthrough Cancer Therapy Developer, Alpha Tau, Awarded ISO 13485 Certificate for Quality Management of Medical Devices

April 11, 2019

1/5
Please reload

Archive
Please reload

Follow Us
  • Grey Facebook Icon
  • Grey LinkedIn Icon
  • Grey Twitter Icon
  • Grey Facebook Icon
  • Grey LinkedIn Icon
  • Grey Twitter Icon

CONTACT US

Are you looking to participate in clinical trials?

Take our self-assessment test to find potentially suitable studies.

For other inquiries, please visit our contact page.